Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors

Restricted access

Objectives: Aromatase inhibitors (AIs) are standard adjuvant therapy for postmenopausal women with early-stage, estrogen receptor–positive breast cancer. We designed our study to determine whether women initiating adjuvant therapy with an AI underwent baseline bone mineral density testing, as well as what factors predicted adherence with testing guidelines. Methods: Medicare Parts A, B, and D claims were used to identify a cohort of women aged 67 years and older with incident breast cancer in 2006 and 2007 who started AI therapy. Medicare claims provided information about bone density testing, as well as demographic and other treatment data through 2012. We also ascertained which patients were treated with bisphosphonates and studied the relationship of bisphosphonate therapy with bone density testing. Results: Approximately two-thirds of patients had baseline bone density testing. Older age, comorbidity, low income, and black race were associated with lower rates of baseline bone density testing. Testing rates decreased substantially with increasing age from 73% for women aged 67 to 70 years to 51% for those 85 years of age and older (adjusted odds ratio for not being tested, 2.48 [Cl, 2.17–2.82]). The proportion of women who had neither bone density testing nor bisphosphonate therapy increased with age as well. Conclusions: Despite the importance of age as a risk factor for fractures, older women starting treatment with AIs for treatment of breast cancer are less likely to undergo recommended bone density assessment.

Correspondence: John Charlson, MD, Hematology-Oncology Division, Department of Medicine, 9200 Wisconsin Avenue, Medical College of Wisconsin, Milwaukee, WI 53226. E-mail: jcharlso@mcw.edu

Author Contributions: Study concepts: Neuner and Charlson. Study design: Neuner, Charlson, and Laud. Data acquisition: Neuner. Quality control of data and algorithms: Laud and Smith. Data analysis and interpretation: Neuner, Laud, Smith, Charlson, and Smallwood. Statistical analysis: Laud and Smith. Manuscript preparation: Neuner, Charlson, Smallwood, Laud, and Smith. Manuscript editing: Neuner, Charlson, and Smallwood. Manuscript review: Neuner, Charlson, Smallwood, Laud, and Smith.

  • 1.

    Yen TW, Czypinski LK, Sparapani RA. Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. Cancer 2011;117:398405.

    • Search Google Scholar
    • Export Citation
  • 2.

    Amir E, Seruga B, Niraula S. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103:12991309.

    • Search Google Scholar
    • Export Citation
  • 3.

    Neuner JM, Yen TW, Sparapani RA. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int 2011;22:28472855.

    • Search Google Scholar
    • Export Citation
  • 4.

    Lonning PE, Geisler J, Krag LE. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:51265137.

    • Search Google Scholar
    • Export Citation
  • 5.

    Gralow JR, Biermann JS, Farooki A. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw 2013;11(Suppl 3):S150.

  • 6.

    Hillner BE, Ingle JN, Chlebowski RT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:40424057.

    • Search Google Scholar
    • Export Citation
  • 7.

    Lim LS, Hoeksema LJ, Sherin K. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009;36:366375.

    • Search Google Scholar
    • Export Citation
  • 8.

    Nelson HD, Haney EM, Dana T. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2010;153:99111.

    • Search Google Scholar
    • Export Citation
  • 9.

    Earle CC, Burstein HJ, Winer EP. Quality of non–breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 2003;21:14471451.

    • Search Google Scholar
    • Export Citation
  • 10.

    Snyder CF, Frick KD, Kantsiper ME. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 2009;27:10541061.

    • Search Google Scholar
    • Export Citation
  • 11.

    Ligibel J, O'Malley AJ, Fisher M. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat 2012;134:13051313.

    • Search Google Scholar
    • Export Citation
  • 12.

    Spangler L, Yu O, Loggers E. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Women's Health 2013;22:132140.

    • Search Google Scholar
    • Export Citation
  • 13.

    Early Breast Cancer Trialists' Collaborative Group: aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:13411352.

    • Search Google Scholar
    • Export Citation
  • 14.

    Nattinger AB, Laud PW, Bajorunaite R. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 2004;39(6 Pt 1):17331749.

    • Search Google Scholar
    • Export Citation
  • 15.

    Klabunde CN, Legler JM, Warren JL. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17:584590.

    • Search Google Scholar
    • Export Citation
  • 16.

    Howell A, Cuzick J, Baum M. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:6062.

    • Search Google Scholar
    • Export Citation
  • 17.

    van de Velde CJ, Rea D, Seynaeve C. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011;377:321331.

    • Search Google Scholar
    • Export Citation
  • 18.

    Dhesy-Thind SK. Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more? J Clin Oncol 2012;30:14081410.

    • Search Google Scholar
    • Export Citation
  • 19.

    Jacobsen SJ, Goldberg J, Miles TP. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health 1990;80:871873.

    • Search Google Scholar
    • Export Citation
  • 20.

    Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988;81:18041809.

  • 21.

    Banks E, Reeves GK, Beral V. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLOS Med 2009;6:e1000181.

    • Search Google Scholar
    • Export Citation
  • 22.

    Neuner JM, Binkley N, Sparapani RA. Bone density testing in older women and its association with patient age. J Am Geriatr Soc 2006;54:485489.

    • Search Google Scholar
    • Export Citation
  • 23.

    Curtis JR, Carbone L, Cheng H. Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res 2008;23:10611067.

    • Search Google Scholar
    • Export Citation
  • 24.

    Aft R, Naughton M, Trinkaus K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421428.

    • Search Google Scholar
    • Export Citation
  • 25.

    Gnant M, Mlineritsch B, Stoeger H. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011;12:631641.

    • Search Google Scholar
    • Export Citation
  • 26.

    Eidtmann H, de Boer R, Bundred N. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21:21882194.

    • Search Google Scholar
    • Export Citation
  • 27.

    Persson I, Adami HO, McLaughlin JK. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control 1994;5:523528.

    • Search Google Scholar
    • Export Citation
  • 28.

    Newcomb PA, Trentham-Dietz A, Egan KM. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol 2001;153:10711078.

  • 29.

    Ganry O, Peng J, Dubreuil A. Is there a reduced risk of breast cancer among women with hip fractures? Eur J Epidemiol 1999;15:313315.

  • 30.

    Chen Z, Maricic M, Aragaki A. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int 2009;20:527536.

    • Search Google Scholar
    • Export Citation
  • 31.

    Ito K, Blinder VS, Elkin EB. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol 2012;30:14681475.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 208 170 6
PDF Downloads 27 21 1
EPUB Downloads 0 0 0